Latest / GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News
Lilly's Retatrutide Eased Sleep Apnea in Two Phase 3 Trials, NEJM Study Reports
Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts on GIP, GLP-1 and glucagon receptors, reduced the severity of moderate-to-severe obstructive sleep apnea more than placebo over 80 weeks in adults with obesity or overweight. We go through the numbers from TRIUMPH-1-OSA (243 participants without type 2 diabetes) and TRIUMPH-2-OSA (448 participants with type 2 diabetes): changes in the apnea-hypopnea index and body weight compared with placebo, how many participants reached no or mild…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.